A Multicenter, dOuble-blind, ranDomized, Placebo-controlled, Parallel-group Study to Determine the effIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With FabrY Disease
Phase of Trial: Phase III
Latest Information Update: 24 Dec 2019
Price : $35 *
At a glance
- Drugs Lucerastat (Primary)
- Indications Fabry's disease
- Focus Registrational; Therapeutic Use
- Acronyms MODIFY
- Sponsors Idorsia Pharmaceuticals
- 20 Dec 2019 Planned End Date changed from 15 Jun 2020 to 15 Jun 2021.
- 20 Dec 2019 Planned primary completion date changed from 15 May 2020 to 15 May 2021.
- 15 Oct 2019 Planned End Date changed from 20 Jun 2020 to 15 Jun 2020.